Anti-PIM1 Rabbit Polyclonal Antibody for WB, IHC-P, ELISA - P11309

Core Product Specifications and Parameters

Biological Background: PIM1 Function and Localization

• Proto-oncogene with serine/threonine kinase activity that promotes cell survival and proliferation, conferring a selective advantage in tumorigenesis. Related references: PMID:15528381, PMID:1825810, PMID:31548394

• Regulates MYC transcriptional activity, cell cycle progression, and phosphorylates/inhibits proapoptotic proteins (BAD, MAP3K5, FOXO3). Related references: PMID:18593906

• Mediates survival signaling by phosphorylating BAD, leading to release of the anti-apoptotic protein Bcl-X(L).

• Inhibits MAP3K5 (ASK1) kinase activity, blocking JNK/p38-mediated phosphorylation and caspase-3 activation to suppress apoptosis. Related references: PMID:19749799

• Stimulates cell cycle progression by phosphorylating CDC25A and CDC25C at G1-S and G2-M transitions, stabilizes CDKN1A via cytoplasmic relocation, and promotes degradation of CDKN1B. Related references: PMID:16356754, PMID:12431783, PMID:18593906

• Modulates chromatin structure via phosphorylation of HP1γ/CBX3. Related references: PMID:10664448

• Regulates mTORC1 signaling by phosphorylating and inhibiting DEPDC5; inactivates GBP1 to modulate innate immunity; phosphorylates ABCG2 to promote drug resistance. Related references: PMID:31548394, PMID:37797010, PMID:18056989

• Predominantly expressed in hematopoietic and germline cells, with isoforms detected in prostate cancer; localizes to cytoplasm, nucleus, and cell membrane.

Experimental Guidance and Technical Tips

• The immunogen is a recombinant protein covering amino acids 1-313 (NP_001230115.1). This full-length design may detect multiple isoforms; validate specificity in the relevant experimental system.
• For Western blotting, the predicted molecular weight is 36 kDa; post-translational modifications may cause band shifts—use appropriate positive and negative controls.
• IHC-P applications should include validation on tissues with known PIM1 expression, such as hematopoietic or prostate cancer samples.
• In ELISA, consider employing the recombinant immunogen as a standard or coating antigen to confirm antibody reactivity.
• Cross-reactivity with mouse and rat enables use in rodent models; optimize secondary antibody and blocking conditions for each species.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers comprehensive IVD raw-material supply solutions for diagnostic manufacturers, research laboratories, and institutes. For oncology and kinase research, this anti-PIM1 antibody complements our portfolio of validated antibody pairs, optimized polyclonal and monoclonal antibodies, and bulk ancillary reagents. Our one-stop platform streamlines procurement from concept to clinic, including sourcing for rare targets and technical consulting.